Therapy and prophylaxis of opportunistic infections in HIV-infected patients: A guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)

Infection

Volumn 41, Issue SUPPL. 2, 2013, Pages

  Thoden, J ^a   Potthoff, A ^b   Bogner, J R ^c   Brockmeyer, N H ^b   Esser, S ^d   Grabmeier Pfistershammer, K ^e   Haas, B ^f   Hahn, K ^g   Harter G ^h   Hartmann, M ⁱ   Herzmann, C ^j   Hutterer, J ^k   Jordan, A R ^l   Lange, C ^j   Mauss, S ^m   Meyer Olson, D ⁿ   Mosthaf, F ^o   Oette, M ^p   Reuter, S ^q   Rieger, A ^e   Rosenkranz, T ^r   Ruhnke, M ^g   Schaaf, B ^s   Schwarze, S ^t   Stellbrink, H J ^u   Stocker, H ^v   Stoehr, A ^r   Stoll, M ⁿ   Trader C ^v   Vogel, M ^w   Wagner, D ^x   Wyen, C ^y   Hoffmann, C ^u   more..

^a Private Practice Dr C Scholz and Dr J Thoden   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY OF VIENNA   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL ULM   (Germany)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^j RESEARCH CENTER BORSTEL   (Germany)

^k Physician in Private Practice   (Austria)

^l UNIVERSITY OF WITTEN HERDECKE   (Germany)

^m Center for HIV and Hepatogastroenterology   (Germany)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o Private Practice Hematology Onkology und Infectious Diseases   (Germany)

^p Department of General Medicine Gastroenterology and Infectious Diseases Augustinerinnen Hospital   (Germany)

^q KLINIKUM LEVERKUSEN   (Germany)

^r DEPARTMENT OF CARDIOLOGY   (Germany)

^s KLINIKUM DORTMUND   (Germany)

^t Projekt Information EV   (Germany)

^u Infektionsmedizinisches Centrum Hamburg   (Germany)

^v Vivantes Auguste Viktoria Klinikum   (Germany)

^w Vivantes Auguste Viktoria Klinikum ^*  (Germany)

^x Molecular Epidemiology   (Germany)

^y UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

more..

Author keywords

Austrian; German; Guidelines; Opportunistic infections; Prophylaxis; Therapy

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ATOVAQUONE; CHLORHEXIDINE; CIDOFOVIR; CLINDAMYCIN; CORTICOSTEROID; DAPSONE; FAMCICLOVIR; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; IMIDAZOLE; ISONIAZID; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; POSACONAZOLE; PRIMAQUINE; PYRIMETHAMINE; PYRROLE DERIVATIVE; RIBAVIRIN; SULFADIAZINE; SULFAMETHOXAZOLE; SULFONAMIDE; THALIDOMIDE; TRIMETHOPRIM; UNINDEXED DRUG; VALACICLOVIR;

ADULT RESPIRATORY DISTRESS SYNDROME; ATYPICAL MYCOBACTERIUM; BRAIN BIOPSY; BRAIN VENTRICULITIS; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTRAST ENHANCEMENT; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DISEASE COURSE; ENCEPHALITIS; ESOPHAGUS CANDIDIASIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENITAL HERPES; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION PREVENTION; INTRACRANIAL HYPERTENSION; LATENT TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RESPIRATORY FAILURE; REVIEW; TOOTHBRUSH; TOXOPLASMOSIS; VACCINATION; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AUSTRIA; CHILD; GERMANY; AIDS RELATED COMPLEX; ARTICLE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AUSTRIA; CHILD; GERMANY; HUMANS;

EID: 84897361739     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0504-1     Document Type: Review

References (233)

1. Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections - going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48:609-11. doi:10.1086/596756.
2. Mussini C, Manzardo C, Johnson M, Monforte A, Uberti-Foppa C, Antinori A, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS. 2008;22:2461-9. doi:10.1097/QAD.0b013e328314b5f1.
3. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207; quiz CE1-4.
4. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;349:1443-5. doi:10.1016/S0140-6736(96)11431-8. (Pubitemid 27212193)
5. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 1998;351:252-5. doi:10.1016/S0140-6736(97)04352-3. (Pubitemid 28043950)
6. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57:167-70. doi:10.1093/jac/dki444. (Pubitemid 43160154)
7. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2009;48:101-7. doi:10.1086/595006.
8. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006;42:1639-46. doi:10.1086/503903.
9. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516-23. doi:10.1016/S1473-3099(08)70184-1. (Pubitemid 352005824)
10. Haddow LJ, Easterbrook PJ, Mosam A, Khanyile NG, Parboosing R, Moodley P, et al. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis. 2009;49:1424-32. doi:10.1086/630208.
11. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006;42:418-27. doi:10.1086/499356. (Pubitemid 43122323)
12. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008;22:601-10. doi:10.1097/QAD. 0b013e3282f4a607. (Pubitemid 351640593)
13. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251-61. doi:10.1016/S1473-3099(10)70026-8.
14. Wahlers K. Immunereconstitution inflammatory syndrome in a prospective German cohort. Abstract 149. KIT. 2010.
15. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007;21:335-41. doi:10.1097/QAD. 0b013e328011efac. (Pubitemid 46175045)
16. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE. 2009;4:e5575. doi:10.1371/journal.pone.0005575.
17. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365(16):1492-1501. doi:10.1056/NEJMoa1014181.
18. Makadzange AT, Ndhlovu CE, Takarinda K, Reid M, Kurangwa M, Gona P, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. 2010;50:1532-8. doi:10.1086/652652.
19. Sungkanuparph S, Filler SG, Chetchotisakd P, Pappas PG, Nolen TL, Manosuthi W, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with Cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis. 2009;49:931-4. doi:10.1086/605497.
20. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24:2381-90. doi:10.1097/QAD.0b013e32833dfc68.
21. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291-322. doi:10.1086/649858.
22. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007;44:94-102. doi:10.1086/510080. (Pubitemid 44968992)
23. Park WB, Choe PG, Jo JH, Kim SH, Bang JH, Kim HB, et al. Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome. AIDS. 2006;20:2390-2. doi:10.1097/QAD. 0b013e328010f201. (Pubitemid 44789544)
24. Confalonieri M, Calderini E, Terraciano S, Chidini G, Celeste E, Puccio G, et al. Noninvasive ventilation for treating acute respiratory failure in AIDS patients with Pneumocystis carinii pneumonia. Intensive Care Med. 2002;28:1233-8. doi:10.1007/s00134-002-1395-2. (Pubitemid 35025040)
25. Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009;17:1-7.
26. Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev. 2006;19(3):CD006150.
27. Arasteh K, Heise W, L'Age M. Treatment of mild to moderately severe Pneumocystis carinii pneumonia with cotrimoxazole versus pentamidine aerosol. Preliminary results of a prospective randomized therapy study. Med Klin (Munich). 1990;85:260-3. (Pubitemid 20186513)
28. Montgomery AB, Feigal DW Jr, Sattler F, Mason GR, Catanzaro A, Edison R, et al. Pentamidine aerosol versus trimethoprim-sulfamethoxazole for Pneumocystis carinii in acquired immune deficiency syndrome. Am J Respir Crit Care Med. 1995;151:1068-74.
29. Conte JE Jr, Chernoff D, Feigal DW Jr, Joseph P, McDonald C, Golden JA. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med. 1990;113:203-9. (Pubitemid 20242296)
30. Soo Hoo GW, Mohsenifar Z, Meyer RD. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med. 1990;113:195-202. (Pubitemid 20242295)
31. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep. 2004;53:1-112.
32. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521-7. doi:10.1056/NEJM199305273282103. (Pubitemid 23147781)
33. Dohn MN, Weinberg WG, Torres RA, Follansbee SE, Caldwell PT, Scott JD, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med. 1994;121:174-80. (Pubitemid 24225633)
34. Toma E, Thorne A, Singer J, Raboud J, Lemieux C, Trottier S, et al. Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group. Clin Infect Dis. 1998;27:524-30.
35. Benfield T, Atzori C, Miller RF, Helweg-Larsen J. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr. 2008;48:63-7. doi:10.1097/QAI.0b013e31816de84d. (Pubitemid 351600861)
36. Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009;64:1282-90. doi:10.1093/jac/dkp372.
37. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177-88. (Pubitemid 26024752)
38. DiRienzo AG, van Der Horst C, Finkelstein DM, Frame P, Bozzette SA, Tashima KT. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses. 2002;18:89-94. doi:10.1089/ 08892220252779629. (Pubitemid 34161227)
39. El-Sadr WM, Luskin-Hawk R, Yurik TM, Walker J, Abrams D, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of PCP in HIV-infected persons. Clin Infect Dis. 1999;29:775-83. (Pubitemid 30256366)
40. Leoung GS, Stanford JF, Giordano MF, Stein A, Torres RA, Giffen CA, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 2001;184:992-7. doi:10.1086/323353. (Pubitemid 32955115)
41. Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:104-14.
42. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995;332:693-9. doi:10.1056/NEJM199503163321101.
43. El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HH Jr, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med. 1998;339:1889-95. doi:10.1056/NEJM199812243392604. (Pubitemid 29013932)
44. Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis. 1999;180:369-76. doi:10.1086/314893. (Pubitemid 30256317)
45. Rosenberg DM, McCarthy W, Slavinsky J, Chan CK, Montaner J, Braun J, et al. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS. 2001;15:211-4. (Pubitemid 32142296)
46. Schneider MM, Borleffs JC, Stolk RP, Jaspers CA, Hoepelman AI. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet. 1999;353:201-3. doi:10.1016/S0140-6736(98)07204-3. (Pubitemid 29088032)
47. Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzales-Lahoz J, d'Arminio Monforte A et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroS-IDA Study Group. Lancet. 1999;353:1293-8. (Pubitemid 29178778)
48. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, Podzamczer D, Alberdi JC, Martinez E et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med. 2001;344:159-67. doi:10.1056/NEJM200101183440301. (Pubitemid 32064136)
49. Abgrall S, Matheron S, Le Moing V, Dupont C, Costagliola D. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis. J Acquir Immune Defic Syndr. 2001;26:151-8. (Pubitemid 32224186)
50. Degen O, ven Lunzen J, Horstkotte MA, Sobottka I, Stellbrink HJ. Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxis. AIDS. 2002;16(10):1433-4. (Pubitemid 34722081)
51. Mussini C, Pezzotti P, Antinori A, Borghi V, Monforte A, Govoni A, et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis. 2003;36:645-51. doi:10.1086/367659. (Pubitemid 36259572)
52. D'Egidio GE, Kravcik S, Cooper CL, Cameron DW, Fergusson DA, Angel JB. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4 + T-cell count <200 cells/microl when viral replication is suppressed. AIDS. 2007;21:1711-5. doi:10.1097/QAD.0b013e32826fb6fc. (Pubitemid 47237557)
53. Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis. 2001;33:1747-55. doi:10.1086/322622. (Pubitemid 33044543)
54. Antinori A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, et al. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis. 2004;39:1681-91. doi:10.1086/424877. (Pubitemid 39578546)
55. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992;116:33-43.
56. Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG, et al. Treatment of central nervous system toxoplasmosis with pyrimethamine/ sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med. 1988;84(1):94-100.
57. Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. 1996;22:268-75. (Pubitemid 26056155)
58. Canessa A, Del Bono V, De Leo P, Piersantelli N, Terragna A. Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1992;11:125-30. .
59. Beraud G, Pierre-Francois S, Foltzer A, Abel S, Liautaud B, Smadja D, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. Am J Trop Med Hyg. 2009;80:583-7.
60. Torre D, Casari S, Speranza F, Donisi A, Gregis G, Poggio A, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine- sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. 1998;42:1346-9. (Pubitemid 28257629)
61. Soheilian M, Sadoughi MM, Ghajarnia M, Dehghan MH, Yazdani S, Behboudi H, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;112:1876-82. doi:10.1016/j.ophtha.2005.05.025.
62. Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst Rev. 2006;3:CD005420. doi:10.1002/14651858.CD005420.pub2.
63. Luft BJ, Chua A. Central nervous system toxoplasmosis in HIV pathogenesis, diagnosis, and therapy. Curr Infect Dis Rep. 2000;2:358-62.
64. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis. 2002;34:1243-50. doi:10.1086/339551. (Pubitemid 34450673)
65. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, van Ruyven RL, Klok AM, Hoyng CB, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:34-40. (Pubitemid 34722707)
66. Wallace MR, Rossetti RJ, Olson PE. Cats and toxoplasmosis risk in HIV-infected adults. JAMA. 1993;269:76-7. (Pubitemid 23006527)
67. Podzamczer D, Miro JM, Ferrer E, Gatell JM, Ramon JM, Ribera E, et al. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group. Eur J Clin Microbiol Infect Dis. 2000;19:89-95. (Pubitemid 30139393)
68. Ribera E, Fernandez-Sola A, Juste C, Rovira A, Romero FJ, Armadans-Gil L, et al. Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. 1999;29:1461-6. doi:10.1086/313515. (Pubitemid 30022741)
69. Duval X, Pajot O, Le Moing V, Longuet P, Ecobichon JL, Mentre F, et al. Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy. AIDS. 2004;18:1342-4. (Pubitemid 38822716)
70. Miro JM, Lopez JC, Podzamczer D, Pena JM, Alberdi JC, Martinez E, et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis. 2006;43:79-89. doi:10.1086/504872. (Pubitemid 43939080)
71. Fournier S, Rabian C, Alberti C, Carmagnat MV, Garin JF, Charron D, et al. Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens. J Infect Dis. 2001;183:1586-91. doi:10.1086/320706. (Pubitemid 32466695)
72. Furco A, Carmagnat M, Chevret S, Garin YJ, Pavie J, De Castro N, et al. Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAART. AIDS. 2008;22:2087-96. doi:10.1097/QAD.0b013e3283136d68.
73. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med. 1998;158:957-69. (Pubitemid 28213573)
74. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, et al. Restoration of cytomegalovirus-specific CD4 + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998;4:953-6. (Pubitemid 28364037)
75. Deayton J, Mocroft A, Wilson P, Emery VC, Johnson MA, Griffiths PD. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS. 1999;13:1203-6. (Pubitemid 29361089)
76. Labetoulle M, Goujard C, Frau E, Rogier H, Niessen F, Furlan V, et al. Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years. J Acquir Immune Defic Syndr. 1999;22:228-34. (Pubitemid 30012666)
77. Tural C, Romeu J, Sirera G, Andreu D, Conejero M, Ruiz S, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis. 1998;177:1080-3. (Pubitemid 28155167)
78. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167-76. (Pubitemid 29431482)
79. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol. 1999;39:800-4. (Pubitemid 30629438)
80. Polis MA, deSmet MD, Baird BF, Mellow S, Falloon J, Davey RT Jr, et al. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am J Med. 1993;94:175-80. (Pubitemid 23046443)
81. Group AR. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology. 1994;101:1250-61.
82. [No authors listed]. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology. 1994;101(7):1250-61
83. Moyle G, Harman C, Mitchell S, Mathalone B, Gazzard BG. Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. J Infect. 1992;25:21-7.
84. Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis. 1998;177:770-3. (Pubitemid 28099896)
85. Jabs DA, Enger C, Forman M, Dunn JP. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. 1998;42:2240-4. (Pubitemid 28420357)
86. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119-26. (Pubitemid 34984602)
87. Lalezari J, Lindley J, Walmsley S, Kuppermann B, Fisher M, Friedberg D, et al. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr. 2002;30:392-400. (Pubitemid 34857313)
88. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med. 1997;126:257-63.
89. Group AR. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol. 1996;114:23-33.
90. Hatton MP, Duker JS, Reichel E, Morley MG, Puliafito CA. Treatment of relapsed cytomegalovirus retinitis with the sustained-release ganciclovir implant. Retina. 1998;18:50-5. (Pubitemid 28128405)
91. Fuchs AV, Wolf E, Scheider A, Jager H, Kampik A. Cytomegalovirus (CMV) retinitis in AIDS. Gancilovir implantation in comparison with systemic therapy. Ophthalmologe. 1999;96:11-5. (Pubitemid 29146303)
92. Smith CL. Local therapy for cytomegalovirus retinitis. Ann Pharmacother. 1998;32:248-55. (Pubitemid 28082338)
93. Muccioli C, Belfort R Jr. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Braz J Med Biol Res. 2000;33:779-89. (Pubitemid 30604762)
94. Berman SM, Kim RC. The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. Am J Med. 1994;96:415-9. (Pubitemid 24156727)
95. Kalayjian RC, Cohen ML, Bonomo RA, Flanigan TP. Cytomegalovirus ventriculoencephalitis in AIDS. A syndrome with distinct clinical and pathologic features. Medicine (Baltimore). 1993;72(2):67-77. (Pubitemid 23097761)
96. Ewig S, Bierhoff E, Luster W, Steudel A, Niese D. Progressive cytomegalovirus encephalitis in successful ganciclovir therapy of cytomegalovirus retinitis in an AIDS patient. Klin Wochenschr. 1991;69:449-53.
97. Schwarz TF, Loeschke K, Hanus I, Jager G, Feiden W, Stefani FH. CMV encephalitis during ganciclovir therapy of CMV retinitis. Infection. 1990;18:289-90. (Pubitemid 20349309)
98. Mastroianni CM, Ciardi M, Folgori F, Sebastiani G, Vullo V, Delia S, et al. Cytomegalovirus encephalitis in two patients with AIDS receiving ganciclovir for cytomegalovirus retinitis. J Infect. 1994;29:331-7. (Pubitemid 24365191)
99. Cinque P, Baldanti F, Vago L, Terreni MR, Lillo F, Furione M, et al. Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection in cerebrospinal fluid. J Infect Dis. 1995;171:1603-6.
100. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis. 1998;177:1182-7. (Pubitemid 28194255)
101. Jouan M, Saves M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2001;15:23-31. (Pubitemid 32055776)
102. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2:73-85. (Pubitemid 36114141)
103. Reinel D, Plettenberg A, Seebacher C, Abeck D, Brasch J, Effendy I, et al. Oral candidiasis. J Dtsch Dermatol Ges. 2004;2:874-6.
104. Mendling W, Seebacher C. Guideline vulvovaginal candidosis: guideline of the German Dermatological Society, the German Speaking Mycological Society and the Working Group for Infections and Infectimmunology of the German Society for Gynecology and Obstetrics. Mycoses. 2003;46:365-9. (Pubitemid 37412034)
105. Flynn PM, Cunningham CK, Kerkering T, San Jorge AR, Peters VB, Pitel PA, et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. J Pediatr. 1995;127(2):322-8.
106. Hood S, Evans J, Bond J, Wilkins E, Denning D. The treatment of oropharyngeal candidiasis in HIV-infected patients with oral amphotericin B suspension. AIDS Patient Care STDS. 1998;12(8):625-7. (Pubitemid 28411391)
107. Pons V, Greenspan D, Lozada-Nur F, McPhail L, Gallant JE, Tunkel A. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis. 1997;24(6):1204-7.
108. Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42:1179-86. doi:10.1086/501457.
109. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis. 1995;27:613-7. (Pubitemid 26089493)
110. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33:1447-54. doi:10.1086/322653. (Pubitemid 34246135)
111. Phillips P, De Beule K, Frechette G, Tchamouroff S, Vandercam B, Weitner L, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis. 1998;26:1368-73. (Pubitemid 28270167)
112. Ruhnke M. Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment. Drugs. 2004;64:1163-80 64112 [pii].
113. Hamza OJ, Matee MI, Bruggemann RJ, Moshi MJ, Simon EN, Mugusi F, et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis. 2008;47:1270-6. doi:10.1086/592578.
114. Chave JP, Cajot A, Bille J, Glauser MP. Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: a pilot study. J Infect Dis. 1989;159:806-7. (Pubitemid 19105645)
115. Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution-effective treatment for HIV-related candidosis unresponsive to other azole therapy. J Antimicrob Chemother. 1994;33:1071-3. (Pubitemid 24170919)
116. Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS. 1998;12:2227-8. (Pubitemid 28495279)
117. Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44:607-14. doi:10.1086/511039. (Pubitemid 46233269)
118. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials. 2007;8:86-97. doi:10.1310/hct0802-86. (Pubitemid 46953299)
119. Penk A, Pittrow L. High-dose therapy with fluconazole >or =800 mg/day. Review. Mycoses. 1997;40:33-42. (Pubitemid 27475194)
120. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113:294-9. (Pubitemid 35287295)
121. de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21(7):899-907. doi:10.1111/j.1365-2036.2005.02427.x. (Pubitemid 40477250)
122. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39:770-5. doi:10.1086/423378. (Pubitemid 39244288)
123. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr. 2008;48:304-9. doi:10.1097/QAI.0b013e31817af47a.
124. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001;33:1529-35. doi:10.1086/323401. (Pubitemid 34246147)
125. Valdez H, Gripshover BM, Salata RA, Lederman MM. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS. 1998;12:538. (Pubitemid 28116169)
126. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;27:1291-4. (Pubitemid 29242485)
127. Barasch A, Safford MM, Dapkute-Marcus I, Fine DH. Efficacy of chlorhexidine gluconate rinse for treatment and prevention of oral candidiasis in HIV-infected children: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:204-7. doi:10.1016/S1079210403005651. (Pubitemid 38224052)
128. Nittayananta W, DeRouen TA, Arirachakaran P, Laothumthut T, Pangsomboon K, Petsantad S, et al. A randomized clinical trial of chlorhexidine in the maintenance of oral candidiasis-free period in HIV infection. Oral Dis. 2008;14:665-70. doi:10.1111/j.1601-0825.2008.01449.x.
129. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;174:821-7. (Pubitemid 26325900)
130. Fan-Havard P, Capano D, Smith SM, Mangia A, Eng RH. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991;35:2302-5.
131. Goldman M, Cloud GA, Wade KD, Reboli AC, Fichtenbaum CJ, Hafner R, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis. 2005;41:1473-80. doi:10.1086/497373. (Pubitemid 41579992)
132. Chen XS, Han GZ, Guo ZP, Lu NZ, Chen J, Wang JB. A comparison of topical application of penciclovir 1% cream with acyclovir 3% cream for treatment of genital herpes: a randomized, double-blind, multicentre trial. Int J STD AIDS. 2000;11:568-73.
133. Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis. 2004;39:S248-57. doi:10.1086/422364. (Pubitemid 39447300)
134. Phiri S, Hoffman IF, Weiss HA, Martinson F, Nyirenda N, Kamwendo D, et al. Impact of aciclovir on ulcer healing, lesional, genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi. Sex Transm Infect. 2010;86:345-52. doi:10.1136/sti.2009.041814.
135. Ormrod D, Scott LJ, Perry CM. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs. 2000;59:839-63. (Pubitemid 30232326)
136. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS. 2002;13:12-21. (Pubitemid 34032997)
137. Vinh DC, Aoki FY. Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective. Expert Opin Pharmacother. 2006;7:2271-86. doi:10.1517/14656566.7.16.2271.
138. Bodsworth N, Bloch M, McNulty A, Denham I, Doong N, Trottier S, et al. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sex Health. 2008;5:219-25 SH08013 [pii].
139. Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS. J Acquir Immune Defic Syndr. 1992;5:S29-32.
140. Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis. 1998;178:349-59. (Pubitemid 28347916)
141. DeJesus E, Wald A, Warren T, Schacker TW, Trottier S, Shahmanesh M, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188:1009-16. doi:10.1086/378416. (Pubitemid 37268251)
142. Warren T, Harris J, Brennan CA. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. Clin Infect Dis. 2004;39:S258-66. doi:10.1086/422362. (Pubitemid 39447301)
143. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73-83. (Pubitemid 41818117)
144. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2109-19. doi:10.1016/S0140-6736(08) 60920-4. (Pubitemid 351902179)
145. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427-39. doi:10.1056/NEJMoa0904849.
146. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358:1560-71. doi:10.1056/NEJMoa0800260. (Pubitemid 351519816)
147. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340-6. doi:10.1056/NEJMcp013211.
148. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2009(2):CD006866. doi:10.1002/14651858.CD006866.pub2.
149. Gershon AA. Prevention and treatment of VZV infections in patients with HIV. Herpes. 2001;8:32-6. (Pubitemid 32625612)
150. Saint-Leger E, Caumes E, Breton G, Douard D, Saiag P, Huraux JM, et al. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis. 2001;33:2061-7. doi:10.1086/324503. (Pubitemid 33152402)
151. Albrecht H, Hoffmann C, Degen O, Stoehr A, Plettenberg A, Mertenskotter T, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998;12:1149-54. (Pubitemid 28302416)
152. Hernandez B, Dronda F, Moreno S. Treatment options for AIDS patients with progressive multifocal leukoencephalopathy. Expert Opin Pharmacother. 2009;10:403-16. doi:10.1517/14656560802707994.
153. Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology. 1999;52:623-5. (Pubitemid 29075615)
154. Dworkin MS, Wan PC, Hanson DL, Jones JL. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis. 1999;180:621-5. doi:10.1086/314937. (Pubitemid 29411346)
155. Tantisiriwat W, Tebas P, Clifford DB, Powderly WG, Fichtenbaum CJ. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis. 1999;28:1152-4. doi:10.1086/514762. (Pubitemid 29203555)
156. Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2003;36:1047-52. doi:10.1086/374048. (Pubitemid 36513291)
157. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72:1458-64. doi:10.1212/01.wnl.0000343510.08643.74.
158. Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology. 2009;73:1551-8. doi: 10.1212/WNL.0b013e3181c0d4a1.
159. Focosi D, Marco T, Kast RE, Maggi F, Ceccherini-Nelli L, Petrini M. Progressive multifocal leukoencephalopathy: what's new? Neuroscientist. 2010;16:308-23. doi: 10.1177/1073858409356594.
160. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med. 1998;338:1345-51. doi:10.1056/NEJM199805073381903. (Pubitemid 28216663)
161. Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother. 1997;41:587-93. (Pubitemid 27098409)
162. Nukuzuma S, Nakamichi K, Nukuzuma C, Takegami T. Inhibitory effect of serotonin antagonists on JC virus propagation in a carrier culture of human neuroblastoma cells. Microbiol Immunol. 2009;53:496-501. doi:10.1111/j.1348- 0421.2009.00156.x.
163. Chapagain ML, Sumibcay L, Gurjav U, Kaufusi PH, Kast RE, Nerurkar VR. Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol. 2008;14:448-54. doi:10.1080/13550280802235916. (Pubitemid 352762884)
164. Verma S, Cikurel K, Koralnik IJ, Morgello S, Cunningham-Rundles C, Weinstein ZR, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis. 2007;196:709-11. doi:10.1086/520514. (Pubitemid 47293853)
165. Focosi D, Kast RE, Maggi F, Ceccherini-Nelli L, Petrini M. Risperidone-induced reduction in JC viruria as a surrogate marker for efficacy against progressive multifocal leukoencephalopathy and hemorrhagic cystitis. J Clin Virol. 2007;39:63-4. doi:10.1016/j.jcv.2007.03.001. (Pubitemid 46575345)
166. Focosi D, Kast RE, Maggi F, Lauria G, Ceccherini-Nelli L, Petrini M. 5-HT2a inhibitors for progressive multifocal leukoencephalopathy: old drugs for an old disease. J Infect Dis. 2008;197(2):328; author reply -9. doi:10.1086/524877.
167. Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol. 2009;66:255-8. doi:10.1001/archneurol.2008.557.
168. Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother. 2009;53:1840-9. doi:10.1128/AAC.01614-08.
169. Colford JM Jr, Tager IB, Hirozawa AM, Lemp GF, Aragon T, Petersen C. Cryptosporidiosis among patients infected with human immunodeficiency virus. Factors related to symptomatic infection and survival. Am J Epidemiol. 1996;144:807-16. (Pubitemid 26374950)
170. McGowan I, Hawkins AS, Weller IV. The natural history of cryptosporidial diarrhoea in HIV-infected patients. AIDS. 1993;7:349-54. (Pubitemid 23104550)
171. Jablonowski H, Szelenyi H, Becker K, Lubke HJ, Borchard F, Strohmeyer G, et al. Sclerosing cholangitis with papillary stenosis in an HIV-infected patients with Cryptosporidium infection. Z Gastroenterol. 1994;32:441-3. (Pubitemid 24282995)
172. Hashmey R, Smith NH, Cron S, Graviss EA, Chappell CL, White AC, Jr. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore). 1997;76(2):118-39. (Pubitemid 27157666)
173. Gross TL, Wheat J, Bartlett M, O'Connor KW. AIDS and multiple system involvement with cryptosporidium. Am J Gastroenterol. 1986;81:456-8. (Pubitemid 16044143)
174. Travis WD, Schmidt K, MacLowry JD, Masur H, Condron KS, Fojo AT. Respiratory cryptosporidiosis in a patient with malignant lymphoma. Report of a case and review of the literature. Arch Pathol Lab Med. 1990;114:519-22. (Pubitemid 20147439)
175. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet. 1998;351:256-61. doi:10.1016/S0140-6736(97) 07529-6. (Pubitemid 28043951)
176. Miao YM, Awad-El-Kariem FM, Franzen C, Ellis DS, Muller A, Counihan HM, et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:124-9.
177. Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev. 2007(1):CD004932. doi:10.1002/14651858.CD004932.pub2.
178. Gathe JC Jr, Mayberry C, Clemmons J, Nemecek J. Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. J Acquir Immune Defic Syndr. 2008;48:363-4. doi:10.1097/QAI.0b013e31817beb78.
179. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis. 2001;184:103-6. doi:10.1086/321008. (Pubitemid 32568508)
180. Amadi B, Mwiya M, Sianongo S, Payne L, Watuka A, Katubulushi M, et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect Dis. 2009;9:195. doi:10.1186/1471-2334-9-195.
181. White AC Jr, Cron SG, Chappell CL. Paromomycin in cryptosporidiosis. Clin Infect Dis. 2001;32:1516-7. doi:10.1086/320171.
182. Hewitt RG, Yiannoutsos CT, Higgs ES, Carey JT, Geiseler PJ, Soave R, et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis. 2000;31:1084-92. doi:10.1086/318155. (Pubitemid 32299370)
183. Holmberg SD, Moorman AC, Von Bargen JC, Palella FJ, Loveless MO, Ward DJ, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA. 1998;279(5):384-6. (Pubitemid 28133869)
184. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11:1463-71. (Pubitemid 27421177)
185. Sloan D, Dlamini S, Dedicoat M. Management of cryptoccocal meningitis in resource-limited settings: a systematic review. S Afr Med J. 2009;99:310-2.
186. Just-Nubling G. Therapy of candidiasis and cryptococcosis in AIDS. Mycoses. 1994;37:56-63.
187. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363:1764-7. doi:10.1016/S0140- 6736(04)16301-0. (Pubitemid 38698379)
188. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010;50:338-44. doi:10.1086/649861.
189. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997;337:15-21. doi:10.1056/NEJM199707033370103.
190. Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005;56:745-55. doi:10.1093/jac/ dki288. (Pubitemid 41487778)
191. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-31. doi:10.1086/374557. (Pubitemid 36549632)
192. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis. 2004;189:2185-91. doi:10.1086/420829. (Pubitemid 38757190)
193. Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995;332:700-5. doi:10.1056/NEJM199503163321102.
194. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, Alvarez M, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS. 2006;20:2183-91. doi:10.1097/01.aids. 0000252060.80704.68. (Pubitemid 44684709)
195. Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS. 2010;24:1549-59. doi:10.1097/QAD.0b013e32833a3967.
196. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis. 2004;4:557-65. doi:10.1016/S1473-3099(04)01130-2. (Pubitemid 39141797)
197. Lange CG, Woolley IJ, Brodt RH. Disseminated Mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated? Drugs. 2004;64:679-92. (Pubitemid 38471370)
198. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416. doi:10.1164/rccm.200604-571ST.
199. Dunne M, Fessel J, Kumar P, Dickenson G, Keiser P, Boulos M, et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis. 2000;31:1245-52. doi:10.1086/317468. (Pubitemid 32295457)
200. Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:1234-43. doi:10.1086/378807. (Pubitemid 37372514)
201. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49:1305-11. doi:10.1086/606056.
202. Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994;121:905-11.
203. Cohn DL, Fisher EJ, Peng GT, Hodges JS, Chesnut J, Child CC, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis. 1999;29:125-33. doi:10.1086/520141. (Pubitemid 29336814)
204. Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis. 1998;27:1278-85. (Pubitemid 29242483)
205. Havlir DV, Schrier RD, Torriani FJ, Chervenak K, Hwang JY, Boom WH. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J Infect Dis. 2000;182:1658-63. doi:10.1086/317620.
206. Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis. 2005;41:1483-97. doi:10.1086/497269. (Pubitemid 41579994)
207. Jt Riddell, Kaul DR, Karakousis PC, Gallant JE, Mitty J, Kazanjian PH. Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl Med. 2007;5:50. doi:10.1186/1479-5876-5-50.
208. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996;335:392-8. doi:10.1056/NEJM199608083350604. (Pubitemid 26257247)
209. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium -intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis. 1992;165:1082-5.
210. Oldfield EC 3rd, Fessel WJ, Dunne MW, Dickinson G, Wallace MR, Byrne W, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis. 1998;26:611-9. (Pubitemid 28155008)
211. Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996;335:384-91. doi:10.1056/ NEJM199608083350603. (Pubitemid 26257246)
212. Lundgren JD, Phillips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:153-60.
213. Ackah AN, Coulibaly D, Digbeu H, Diallo K, Vetter KM, Coulibaly IM, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan. Cote d'Ivoire. Lancet. 1995;345:607-10.
214. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr. 2000;23:75-80. (Pubitemid 30123268)
215. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358:1687-93. doi:10.1016/S0140-6736(01)06712-5. (Pubitemid 33124328)
216. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61:791-4. doi:10.1136/thx.2006.058867. (Pubitemid 44369404)
217. DhedaK, Lampe FC, JohnsonMA, Lipman MC. Outcome ofHIVassociated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004;190:1670-6. doi:10.1086/424676. (Pubitemid 39411018)
218. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med. 2001;164:7-12. (Pubitemid 33151292)
219. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362(8):697-706. doi:10.1056/NEJMoa0905848.
220. Torok ME, Farrar JJ. When to start antiretroviral therapy in HIV-associated tuberculosis. N Engl J Med. 2011;365:1538-40. doi:10.1056/NEJMe1109546.
221. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther. 2005;10:417-22. (Pubitemid 41151019)
222. European AIDS Clinical Society (EACS). Clinical management and treatment of HIV infected adults in Europe, version 5. 2009. Available at: http://wwweuropeanaidsclinicalsocietyorg.
223. Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, National Institutes of Health, Bethesda. 2009:1-161. Available at: http://wwwaidsinfonihgov/ContentFiles/AdultandAdolescentGLpdf
224. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53:2852-6. doi:10.1128/AAC.01468-08.
225. Boyd MA, Zhang X, Dorr A, Ruxrungtham K, Kolis S, Nieforth K, et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol. 2003;43:1382-91. doi:10.1177/0091270003259220. (Pubitemid 37433312)
226. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16:75-83. (Pubitemid 34062184)
227. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-91. doi:10.1056/NEJMoa1013607.
228. Centers for Disease Control and Prevention (CDC). Treatment of latent tuberculosis infection (LTBI). 2007. Available at: http://wwwcdcgov/tb/ publications/factsheets/treatment/treatmentLTBIhtm
229. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48:954-62. doi:10.1086/597351.
230. Centers for Disease Control and Prevention (CDC). Managing drug interactions in the treatment of HIV-related tuberculosis. Division of Tuberculosis Elimination National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. 2007. Available at: http://wwwcdcgov/tb/publications/guidelines/ TB-HIV-Drugs/defaulthtm
231. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004(1):CD000171. doi:10.1002/14651858.CD000171.pub2.
232. Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, et al. Multidrug- and extensively drug-resistant tuberculosis. Germany. Emerg Infect Dis. 2008;14:1700-6.
233. World Health Organization (HO). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. 2010. WHO, Geneva; available at: http://wwwwhoint/tb/en/